TriSalus Life Sciences, Inc.

MedTech Acquisition Corp (Nasdaq: MTAC) is a blank-check company that completed its initial public offering in 2021, targeting the healthcare and medical technology sector. Sponsored by MedTech Acquisition Management LLC, the SPAC announced a definitive business combination agreement with TriSalus Life Sciences, Inc., a clinical-stage oncology company developing pressure-enabled drug delivery systems for the treatment of liver-dominant cancers. The 10-Q filed in May 2022 reflects the company's status during the pendency of that announced merger. The combined company, operating under the TriSalus Life Sciences name, subsequently completed the de-SPAC transaction later that year. For complete filing history, deal terms, and real-time SPAC data, sign up for full access at SpacDesk.